Dr. Heimark currently serves on the Scientific Review panel for the University of Arizona Cancer Center. His background is as a basic scientist in cancer biology, and he is the Vice Chair for Surgical Research in the Department of Surgery. He has been the head of the Scientific Review Committee for the past six years and this committee reviews >100 IRB applications each year for all of surgery divisions except surgical oncology.
Dr. Heimark is aware of the importance of the review process, the regulations for human subjects’ research, and believes that he has the insights to be a successful reviewer. He has a broad scientific expertise and have also been a grant reviewer for NCI as both an ad hoc and a permanent member of the Cancer Biomarkers Study Section.
As the principal investigator and co-PI of several NIH grants, Dr. Heimark believes that he has the scientific expertise and experience required to provide the expertise necessary to review with this outstanding team. His long term goal is to develop a mechanistic understanding and predictive biomarkers of metastatic cancer. His current research builds on his previous work that proposed a role for epithelial-to-mesenchymal transition (EMT) in survival of invasive prostate cancer cells.